Research & Education

Management of ALK Patients With NSCLC: A Multidisciplinary Approach

September 12, 2016 at 8:00PM EST; September 14, 2016 at 9:00PM EST; September 16, 2016 at 11:00PM EST - Recordings Available
Federico Cappuzzo, MD

This sixty-minute webinar will feature 3 presentations:

Practical Approaches to ALK Rearrangement Detection - Lynette Sholl, MD

This presentation will address the pros and cons of in situ, immunohistochemical and molecular approaches to ALK rearrangement detection in lung cancers and will discuss the evolving guidelines for for ALK testing.

Systemic Treatment Options for ALK-Positive NSCLC - Leora Horn, MD

This presentation will address current state-of-the art first line treatment options for patients with ALK-positive NSCLC.

Overcoming resistance to ALK Inhibitors - Alice Shaw, MD

This presentation will review mechanisms of resistance to first and next generation ALK inhibitors, and discuss new and emerging treatment options for patients who develop resistance to one or more ALK inhibitors.

Following the presentation, there will be ample time for discussion and a question/answer session. Attendees will be able to submit questions and comments to the faculty via internet chat.

After attending this program, participants will be able to:

  • Define systemic therapy options for patients with ALK-positive NSCLC.
  • Describe the mechanisms of resistance to first and next generation ALK inhibitors.
  • Demonstrate the evolving state-of-the art of treatment of patients with ALK-positive NSCLC who are resistant to one or more ALK inhibitors.
  • Monitor major, ongoing and planned clinical trials for patients with ALK-positive NSCLC.

Name of Reviewer(s): 


Laurie Gaspar, MD, PhD- Advisory Board/Honoraria: Astrazeneca.

Name of Planner(s): 


Pia Hirsch-Nothing to Disclose      Carlos Ferreira-Nothing to Disclose

Name of Activity: 


Management of ALK Patients With NSCLC: A Multidisciplinary Approach

Date of Activity:






COI Resolution: Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

“All planning committee members’ and/or faculty’s identified conflicts of interest pertaining to this activity were resolved prior to the activity.”

Speaker: Alice Shaw, MD, PhD-Consulting/Honoraria: Pfizer, Novartis, Genentech/Roche, Ariad, EMD Serono, Blueprint medicine, Ignyta, Daiichi-sankyo, Taiho, LOXO.Advisory Board: Blueprint Medicine, KSQ Therapeutics.

Speaker: Lynette Sholl, MD-Advisory Board: Genentech/Roche.

Speaker: Leora Horn, MD-Advisory Boar: BMS, BI, Abbvie, Genentech, Lilly, Merck.Consultant: Xcovery.


Type of Activity:

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?


If yes, please list: Unrestricted grant support by Ariad


Please complete the evaluation link provided to you after the activity. The Certificate of credit will be ready for you to print or save for your records.

Registration is on a first-come, first-served basis. Participation is limited.





IASLC Guidelines For Individuals Planning and/or Presenting a IASLC CME Activity

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)



Continuing medical education consists of educational activities which serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession. The content of CME is that body of knowledge and skills generally recognized and accepted by the profession as within the basic medical sciences, the discipline of clinical medicine, and the provision of health care to the public.

Financial/Commercial Relationships DISCLOSURES

A conflict of interest (COI) is created and exists when individuals in a position to control the content of CME (or their spouses/partners) have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells or distributes health care goods or services consumed by, or used on, patients that benefits the individual in any financial amount and therefore may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds) or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership and other activities for which remuneration is received or expected. 

This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME Department assures that the planners/reviewers/authors/faculty/peer reviewers et al. conflicts of interest were identified, reviewed and resolved fromall individuals involved in the development or able to influence and control the content of this CME activity. The IASLC CME Department assures that disclosure is given prior to an educational activity being delivered to learners. Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from all IASLC CME activity presentations.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee and an independent reviewer. COI will be evaluated by the IASLC Board of Directors for fair balance, scientific objectivity of studies utilized in this activity and patient care recommendations. The IASLC CME Department is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

The intent of this disclosure is not to prevent a speaker with a relevant financial or other relationship from making the presentation, but rather to identify and resolve any conflicts of interest that may control the content of the activity. It is also intended that any potential conflict be identified openly so that the listeners have a full disclosure of the facts and may form their own judgments about the presentation. It remains for the audience to determine whether the speaker’s interests or relationships may influence the presentation with regard to exposition or conclusion.

All other faculty/contributors have reported no commercial affiliation associated with this conference or intent to reference off-label/unapproved uses of products or devices in their presentations.


IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Please complete the evaluation link provided to you after the activity. The certificate of credit will be ready for you to print or save for your records.

How to use the Time Zone Converter